Other Events ·
GT Biopharma, Inc. held its Annual Meeting of Stockholders on August 14, 2026, where shareholders approved several key…
GTBPGT Biopharma, Inc.
GT Biopharma, Inc. held its Annual Meeting of Stockholders on August 14, 2026, where shareholders approved several key proposals. The meeting resulted in the election of four directors: Michael Breen, Charles J. Casamento, Hilary Kramer, and David C. Mun-Gavin. Shareholders also ratified Weinberg & Company, P.A. as independent accountants and approved a non-binding advisory vote on executive compensation. Significantly, stockholders authorized an amendment to the restated certificate of incorporation to permit a reverse stock split at a ratio between 1-for-10 and 1-for-30, alongside a reduction in authorized common shares to 25,000,000 and preferred shares to 1,500,000. The Board retains discretion to determine the specific split ratio and effective date within one year. Additionally, shareholders approved an increase of 3,500,000 shares in the 2022 Omnibus Incentive Plan and adopted an evergreen provision for automatic annual increases. GT Biopharma operates as a clinical-stage biotechnology company focused on developing immunotherapies.